WHO ICTRP trial
Comparison of targeted radiotherapy with and without short-term hormonal…
EUCTR2019-003177-26-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2019-003177-26-NL |
|---|---|
| Public title | Comparison of targeted radiotherapy with and without short-term hormonal treatment (6 months) |
| Scientific title | Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy - ADOPT |
| Primary sponsor | UMCG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =4 metastases;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Eligard, Leuproline acetaat 1x 45 mg sc Product Name: Eligard Pharmaceutical Form: Powder for suspension for injection INN or Proposed INN: LEUPRORELIN ACETATE CAS Number: 74381-53-6 Concentration unit: mg milligram(s)… |
| Registration date | Nov 26, 2019 |
| Target size | 280 |
| Secondary IDs | RT2019-13 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: